Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2023-03-15 Penser Access Penser Access: Intervju med Diamyd Medical - Erik Penser Bank - 15 mars 2023 Pressreleaser Visa Stäng
2023-03-10 Diamyd Medical Diamyd Medical AB: Diamyd Medical brings Karin Rosén, M.D, PhD, to its Board of Directors Pressreleaser Ladda ner | Visa Stäng
2023-03-10 Diamyd Medical Diamyd Medical AB: Dr Karin Rosén till Diamyd Medicals styrelse Pressreleaser Ladda ner | Visa Stäng
2023-02-20 Diamyd Medical Diamyd Medical AB: Patient recruitment for the pivotal Diamyd® Phase 3 trial is progressing according to plan Pressreleaser Ladda ner | Visa Stäng
2023-02-20 Diamyd Medical Diamyd Medical AB: Patientrekrytering till fas 3-studie med Diamyd® fortskrider enligt plan Pressreleaser Ladda ner | Visa Stäng
2023-02-06 Diamyd Medical Diamyd Medical AB: Diamyd Medical receives patent protection in the US and Japan for GABA formulation Remygen® Pressreleaser Ladda ner | Visa Stäng
2023-02-06 Diamyd Medical Diamyd Medical AB: Diamyd Medical erhåller patentskydd i USA och Japan för GABA-formuleringen Remygen® Pressreleaser Ladda ner | Visa Stäng
2023-01-26 Penser Access Penser Access: Full fokus på rekrytering - Diamyd Medical Analyser Visa Stäng
2023-01-25 Diamyd Medical Diamyd Medical AB: Quarterly Report I 22/23 Rapporter Ladda ner | Visa Stäng
2023-01-25 Diamyd Medical Diamyd Medical AB: Delårsrapport I 22/23 Rapporter Ladda ner | Visa Stäng
2022-12-16 Diamyd Medical Diamyd Medical AB: Type 1 Diabetes prevention trial with the antigen-specific immunotherapy Diamyd® approved to start Pressreleaser Ladda ner | Visa Stäng
2022-12-16 Diamyd Medical Diamyd Medical AB: Preventionsstudie för typ 1-diabetes med den antigenspecifika immunoterapin Diamyd® godkänd att starta Pressreleaser Ladda ner | Visa Stäng
2022-12-08 Diamyd Medical Diamyd Medical AB: Update: Diamyd Medical's CEO clarifies comments on the recent approval by FDA of Provention Bio's drug candidate Teplizumab Pressreleaser Ladda ner | Visa Stäng
2022-12-08 Diamyd Medical Diamyd Medical AB: Uppdatering: Diamyd Medicals vd kommenterar FDA:s godkännande av Provention Bios läkemedelskandidat Teplizumab Pressreleaser Ladda ner | Visa Stäng
2022-12-06 Diamyd Medical Diamyd Medical AB: Diamyd Medical precision medicine patent for prevention and treatment of autoimmune diabetes to be granted in Eurasia Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 6 Dec 2022 | Diamyd Medical

Diamyd Medical AB: Diamyd Medical precision medicine patent for prevention and treatment of autoimmune diabetes to be granted in Eurasia

The countries included in the Eurasian cooperation are Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan and Turkmenistan.

HLA DR3-DQ2, associated with autoimmunity against GAD, represents one of the most common genetic risk factors for Type 1 Diabetes since up to 40% of individuals with the disease carry the gene. A large-scale meta-analysis published in Diabetologia in 2020 showed that positivity for HLA DR3-DQ2 is associated with clinical response to the antigen-specific immunotherapy Diamyd[®]. This was prospectively confirmed in the Phase IIb trial DIAGNODE-2, published in Diabetes Care in May 2021. Additional follow-up analyses published in Diabetes, Obesity & Metabolism and The Journal of Clinical Endocrinology & Metabolism in 2022 further showed that the therapeutic effect of Diamyd[®] on preserving endogenous insulin production associates with a statistically significant and clinically relevant effect on improving blood glucose control.

The patent has in additon to Eurasia also been granted in Europe, with additional countries pending. Diamyd Medical holds, as part of an exclusive license from the University of California, Los Angeles (UCLA), patent protection in the United States, which is valid until 2032 for the treatment of diabetes with GAD, a major autoantigen in autoimmune diabetes. Diamyd Medical also holds patent protection valid until 2035 in Europe, China, Japan, Russia, Israel and Australia for intralymphatic administration of Diamyd[®], the administration route used in the ongoing confirmatory Phase III trial with Diamyd[®]. As a biological drug, Diamyd[®] will, independently of patent protection, enjoy twelve and ten years market exclusivity from the date of market approval in the US and Europe respectively.

About Diamyd Medical
Diamyd Medical develops precision medicine therapies for Type 1 Diabetes. Diamyd[®] is an antigen-specific immunotherapy for the preservation of endogenous insulin production. DIAGNODE-3, a confirmatory Phase III trial is actively recruting pateients with recent-onset Type 1 Diabetes in eight European countries. Significant results have previously been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase IIb trial DIAGNODE-2, where Diamyd® was administered directly into a lymph node in children and young adults with recently diagnosed type 1 diabetes. A manufacturing facility is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the antigen-specific immunotherapy Diamyd[®]. Diamyd Medical also develops the GABA-based investigational drug Remygen[®] as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen[®] trial in individuals living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB.

Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.

2022-12-06 Diamyd Medical Diamyd Medical AB: Diamyd Medicals precisionsmedicinska patent för förebyggande och behandling av autoimmun diabetes kommer att beviljas i Eurasien Pressreleaser Ladda ner | Visa Stäng
2022-12-01 Diamyd Medical Bulletin from Annual General Meeting of Diamyd Medical AB Pressreleaser Ladda ner | Visa Stäng
2022-12-01 Diamyd Medical Kommuniké från årsstämma i Diamyd Medical AB Pressreleaser Ladda ner | Visa Stäng
2022-12-01 Diamyd Medical Diamyd Medical AB: Diamyd Medical ger uppdatering inför dagens årsstämma Pressreleaser Ladda ner | Visa Stäng
2022-12-01 Diamyd Medical Diamyd Medical AB: Diamyd Medical provides general update ahead of today's Annual General Meeting Pressreleaser Ladda ner | Visa Stäng
2022-11-29 Diamyd Medical Diamyd Medical AB: Annual Report 21/22 Rapporter Ladda ner | Visa Stäng
2022-11-28 Penser Access Penser Access: Grönt ljus i USA - Diamyd Medical Analyser Visa Stäng
2022-11-26 Diamyd Medical Diamyd Medical AB: FDA häver paus av Fas III-studie med Diamyd® i USA Pressreleaser Ladda ner | Visa Stäng
2022-11-26 Diamyd Medical Diamyd Medical AB: US Partial Clinical Hold on Diamyd® Phase III Trial Lifted by the FDA Pressreleaser Ladda ner | Visa Stäng
2022-11-18 Diamyd Medical Diamyd Medical AB: Diamyd Medicals vd kommenterar FDA:s godkännande av Provention Bios läkemedel Teplizumab Pressreleaser Ladda ner | Visa Stäng
2022-11-18 Diamyd Medical Diamyd Medical AB: Diamyd Medical's CEO comments on the recent approval by FDA of Provention Bio's drug candidate Teplizumab Pressreleaser Ladda ner | Visa Stäng
2022-11-10 Diamyd Medical Diamyd Medical AB: Årsredovisning 21/22 Rapporter Ladda ner | Visa Stäng
2022-10-31 Diamyd Medical Diamyd Medical AB: KALLELSE TILL ÅRSSTÄMMA I DIAMYD MEDICAL AB Pressreleaser Ladda ner | Visa Stäng
2022-10-07 Penser Access Penser Access: Rapportkommentar - Diamyd Medical Analyser Visa Stäng
2022-10-05 Diamyd Medical Diamyd Medical AB: Year-End Report 21/22 Rapporter Ladda ner | Visa Stäng
2022-10-05 Diamyd Medical Diamyd Medical AB: Bokslutskommuniké 21/22 Rapporter Ladda ner | Visa Stäng
2022-09-29 Diamyd Medical Diamyd Medical AB: All patients in DIAGNODE-B have received an additional (booster) injection of Diamyd® Pressreleaser Ladda ner | Visa Stäng
2022-09-29 Diamyd Medical Diamyd Medical AB: Samtliga patienter i DIAGNODE-B har nu fått sin extra (booster) -injektion med Diamyd® Pressreleaser Ladda ner | Visa Stäng
2022-09-20 Diamyd Medical Diamyd Medical AB: Uppdaterade resultat från klinisk studie med Diamyd® presenterades idag på diabeteskonferens Pressreleaser Ladda ner | Visa Stäng
2022-09-20 Diamyd Medical Diamyd Medical AB: Updated results from clinical trial with Diamyd® presented today at diabetes conference Pressreleaser Ladda ner | Visa Stäng
2022-08-05 Diamyd Medical Diamyd Medical AB: 5-månadersresultat från Diamyd®-studie i LADA publicerade i vetenskaplig tidskrift Pressreleaser Ladda ner | Visa Stäng
2022-08-05 Diamyd Medical Diamyd Medical AB: Five-month results from Diamyd® trial in LADA published in peer-reviewed scientific journal Pressreleaser Ladda ner | Visa Stäng
2022-07-07 Diamyd Medical Diamyd Medical AB: Lovande topline-resultat för intralymfatisk Diamyd® hos patienter med LADA Pressreleaser Ladda ner | Visa Stäng
2022-07-07 Diamyd Medical Diamyd Medical AB: Promising topline results for intralymphatic Diamyd® in patients with LADA Pressreleaser Ladda ner | Visa Stäng
2022-06-30 Diamyd Medical Diamyd Medical AB: Diamyd Medical ansluter sig till internationellt konsortium inom typ 1-diabetes Pressreleaser Ladda ner | Visa Stäng
2022-06-30 Diamyd Medical Diamyd Medical AB: Diamyd Medical joins international consortium in Type 1 Diabetes Pressreleaser Ladda ner | Visa Stäng
2022-06-23 Penser Access Penser Access: DIAGNODE-3 har startat - Diamyd Medical Analyser Visa Stäng
2022-06-22 Diamyd Medical Diamyd Medical AB: Delårsrapport III 21/22 Rapporter Ladda ner | Visa Stäng
2022-06-22 Diamyd Medical Diamyd Medical AB: Quarterly Report III 21/22 Rapporter Ladda ner | Visa Stäng
2022-06-06 Diamyd Medical Diamyd Medical AB: Analysis supporting treatment with Diamyd® published in peer-reviewed scientific journal Pressreleaser Ladda ner | Visa Stäng
2022-06-06 Diamyd Medical Diamyd Medical AB: Analys som stöder behandling med Diamyd® publicerad i referentgranskad vetenskaplig tidskrift Pressreleaser Ladda ner | Visa Stäng
2022-05-30 Diamyd Medical Diamyd Medical AB: Immunological analysis of prevention trial with Diamyd® published in peer-reviewed scientific journal Pressreleaser Ladda ner | Visa Stäng
2022-05-30 Diamyd Medical Diamyd Medical AB: Immunologisk analys av preventionsstudie med Diamyd® publicerad i referentgranskad vetenskaplig[ ]tidskrift Pressreleaser Ladda ner | Visa Stäng
2022-05-19 Diamyd Medical Diamyd Medical AB: Första patienten inkluderad i Diamyd Medicals fas III-studie DIAGNODE-3 Pressreleaser Ladda ner | Visa Stäng
2022-05-19 Diamyd Medical Diamyd Medical AB: First patient enrolled in Diamyd Medical's Phase III trial DIAGNODE-3 Pressreleaser Ladda ner | Visa Stäng
2022-05-09 Diamyd Medical Diamyd Medical AB: Diamyd Medicals huvudägare överlämnar hälften av sitt innehav i Diamyd Medical till sina barn Pressreleaser Ladda ner | Visa Stäng
2022-05-09 Diamyd Medical Diamyd Medical AB: Diamyd Medical's principal owner transfers half of his holdings in Diamyd Medical to his children Pressreleaser Ladda ner | Visa Stäng
2022-04-29 Diamyd Medical Diamyd Medical AB: Diamyd®-metaanalys är nu tillgänglig som Open-Access-publikation Pressreleaser Ladda ner | Visa Stäng
2022-04-29 Diamyd Medical Diamyd Medical AB: Diamyd® meta-analysis is now available as Open Access publication Pressreleaser Ladda ner | Visa Stäng
2022-04-20 Diamyd Medical Diamyd Medical AB: New meta-analysis with Diamyd® published in scientific journal Pressreleaser Ladda ner | Visa Stäng
2022-04-20 Diamyd Medical Diamyd Medical AB: Ny metaanalys med Diamyd® publicerad i vetenskaplig tidskrift Pressreleaser Ladda ner | Visa Stäng
2022-04-13 Diamyd Medical Diamyd Medical AB: Ny klinisk studie ska utvärdera en ytterligare injektion (booster) med Diamyd® Pressreleaser Ladda ner | Visa Stäng
2022-04-13 Diamyd Medical Diamyd Medical AB: New clinical trial will evaluate an additional injection (booster) with Diamyd® Pressreleaser Ladda ner | Visa Stäng
2022-04-13 Diamyd Medical Diamyd Medical AB: Huvudägare minskar marginellt sitt innehav i Diamyd Medical med 0,64% Pressreleaser Ladda ner | Visa Stäng
2022-03-31 Penser Access Penser Access: Fas III-studien är i gång - Diamyd Medical Analyser Visa Stäng
2022-03-30 Diamyd Medical Diamyd Medical AB: Delårsrapport II 21/22 Rapporter Ladda ner | Visa Stäng
2022-03-30 Diamyd Medical Diamyd Medical AB: Quarterly Report II 21/22 Rapporter Ladda ner | Visa Stäng
2022-03-28 Diamyd Medical Diamyd Medical AB: Diabetes prevention project coordinated by Diamyd Medical to be presented at scientific conference Pressreleaser Ladda ner | Visa Stäng
2022-03-28 Diamyd Medical Diamyd Medical AB: Diamyd Medical-koordinerat projekt för förebyggande av diabetes presenteras på vetenskaplig konferens Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

5 Apr 2023 | Kvartalsrapport 2023-Q2
28 Jun 2023 | Kvartalsrapport 2023-Q3
11 Oct 2023 | Bokslutskommuniké 2023